Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia
Elpiscience Biopharmaceuticals (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced today that the first patient has been dosed in a Phase 1 clinical trial of its anti-LILRB2 monoclonal antibody ES009 in Australia.